Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease

This study has been completed.
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01042977
First received: January 5, 2010
Last updated: December 18, 2013
Last verified: December 2013
  Purpose

This study is carried out to assess whether dapagliflozin improves glycemic control, decreases fasting plasma glucose levels, body weight and blood pressure when added to patient's existing medications and how it compares with their usual treatment without added dapagliflozin. Safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes and cardiovascular disease


Condition Intervention Phase
Type 2 Diabetes Mellitus
Cardiovascular Disease
Inadequate Glycaemic Control
Drug: Dapagliflozin
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 24-week, Multicentre, Randomised, Double-blind,Age-stratified, Placebo Controlled Phase III Study With an 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg Once Daily in Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Adjusted Mean Change in HbA1c Levels [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    To compare the glycemic efficacy of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease, measured as the mean change in HbA1c from baseline to week 24.

  • Proportion of Responders Meeting All Criteria of a 3-item Endpoint of Clinical Benefit [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    To compare the clinical benefit of dapagliflozin 10 mg versus placebo when added to usual care in type 2 diabetes patients with cardiovascular disease at week 24, measured as the proportion of responders for a 3-item endpoint of clinical benefit, defined as an absolute drop of 0.5% or more from baseline HbA1c, and a relative drop of 3% or more from baseline for total body weight, and an absolute drop of 3 mmHg or more from baseline in seated systolic blood pressure.


Secondary Outcome Measures:
  • Adjusted Mean Percent Change in Body Weight [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    To compare the mean percent change in body weight from baseline to week 24 between dapagliflozin 10 mg versus placebo.

  • Proportion of Participants With a Reduction From Baseline of 5% or More in Body Weight in Participants With Baseline BMI ≥27 kg/m² [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    To compare the proportion of participants with BMI baseline ≥27 kg/m2 with a reduction from baseline of 5% or more in body weight with dapagliflozin 10 mg versus placebo from baseline to week 24. Least Squares Mean represents the percent of participants adjusted for baseline body weight and age stratum.

  • Adjusted Mean Change in Systolic Blood Pressure at Week 8 (LOCF) [ Time Frame: Baseline to Week 8 ] [ Designated as safety issue: No ]
    To compare the mean change in seated systolic blood pressure from baseline to week 8 between dapagliflozin 10 mg versus placebo.

  • Adjusted Mean Change in Seated Systolic Blood Pressure at Week 24 (LOCF) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    To compare the mean change in seated systolic blood pressure from baseline to week 24 between dapagliflozin 10 mg versus placebo.

  • Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) at Week 8 (LOCF) in Participants With Baseline SBP>=130 mmHg [ Time Frame: Baseline to Week 8 ] [ Designated as safety issue: No ]
    To compare the mean change in seated systolic blood pressure (SBP) in participants with baseline seated SBP ≥130 mmHg achieved with dapagliflozin versus placebo from baseline to week 8.


Enrollment: 964
Study Start Date: March 2010
Study Completion Date: December 2012
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
dapagliflozin 10 mg tablet
Drug: Dapagliflozin
10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
Placebo Comparator: 2
matching placebo tablet
Drug: Placebo
matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period

  Eligibility

Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes mellitus.
  • Cardiovascular disease
  • Uninterrupted anti-diabetic treatment for at least 8 weeks before enrolment

Exclusion Criteria:

  • Patients with type 1 diabetes or diabetes insipidus
  • Patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes
  • Any clinically significant illness, which would compromise the patient's safety and their participation in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01042977

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, Arizona
Research Site
Scottsdale, Arizona, United States
United States, California
Research Site
Anaheim, California, United States
Research Site
Bell Gardens, California, United States
Research Site
Chino, California, United States
Research Site
Chula Vista, California, United States
Research Site
Huntington Beach, California, United States
Research Site
Los Angeles, California, United States
Research Site
Mission Hills, California, United States
Research Site
Redondo Beach, California, United States
Research Site
Riverside, California, United States
Research Site
Sacramento, California, United States
Research Site
San Diego, California, United States
Research Site
Torrance, California, United States
United States, Florida
Research Site
Aventura, Florida, United States
Research Site
Boca Raton, Florida, United States
Research Site
Bradenton, Florida, United States
Research Site
Brooksville, Florida, United States
Research Site
Clearwater, Florida, United States
Research Site
Dania, Florida, United States
Research Site
Delray Beach, Florida, United States
Research Site
New Smyrna Beach, Florida, United States
Research Site
Orlando, Florida, United States
United States, Illinois
Research Site
Springfield, Illinois, United States
United States, Indiana
Research Site
Avon, Indiana, United States
Research Site
Franklin, Indiana, United States
Research Site
Greenfield, Indiana, United States
Research Site
Muncie, Indiana, United States
United States, Iowa
Research Site
Waterloo, Iowa, United States
United States, Kansas
Research Site
Topeka, Kansas, United States
United States, Kentucky
Research Site
Paducah, Kentucky, United States
United States, Louisiana
Research Site
Alexandria, Louisiana, United States
United States, Maryland
Research Site
Rockville, Maryland, United States
United States, Michigan
Research Site
Kalamazoo, Michigan, United States
Research Site
Livonia, Michigan, United States
United States, Montana
Research Site
Billings, Montana, United States
United States, New Jersey
Research Site
Berlin, New Jersey, United States
Research Site
Brick, New Jersey, United States
United States, North Carolina
Research Site
Asheboro, North Carolina, United States
United States, North Dakota
Research Site
Fargo, North Dakota, United States
United States, Ohio
Research Site
Cincinnati, Ohio, United States
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Research Site
Altoona, Pennsylvania, United States
Research Site
Erie, Pennsylvania, United States
Research Site
Holland, Pennsylvania, United States
Research Site
Lancaster, Pennsylvania, United States
Research Site
Media, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
United States, Texas
Research Site
Austin, Texas, United States
Research Site
Corpus Christi, Texas, United States
Research Site
Dallas, Texas, United States
Research Site
Irving, Texas, United States
Research Site
Richardson, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Sugarland, Texas, United States
United States, Virginia
Research Site
Alexandria, Virginia, United States
Research Site
Manassas, Virginia, United States
Argentina
Research Site
Buenos Aires, Caba, Argentina
Research Site
Rosario, Santa Fe, Argentina
Research Site
Cordoba, Argentina
Research Site
Salta, Argentina
Research Site
Santa Fe, Argentina
Australia, New South Wales
Research Site
Blacktown, New South Wales, Australia
Research Site
Broadmeadow, New South Wales, Australia
Research Site
Hornsby, New South Wales, Australia
Research Site
Wollongong, New South Wales, Australia
Australia, Queensland
Research Site
Carina Heights, Queensland, Australia
Research Site
Kippa-ring, Queensland, Australia
Australia, South Australia
Research Site
Adelaide, South Australia, Australia
Research Site
Bedford Park, South Australia, Australia
Research Site
Keswick, South Australia, Australia
Australia, Victoria
Research Site
Box Hill, Victoria, Australia
Research Site
Heidelberg, Victoria, Australia
Australia
Research Site
Herston, Australia
Austria
Research Site
Wien, Austria
Bulgaria
Research Site
Blagoevgrad, Bulgaria
Research Site
Pernik, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Russe, Bulgaria
Research Site
Sevlievo, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Stara Zagora, Bulgaria
Research Site
Varna, Bulgaria
Canada, Alberta
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Canada, New Brunswick
Research Site
Moncton, New Brunswick, Canada
Canada, Newfoundland and Labrador
Research Site
Bay Roberts, Newfoundland and Labrador, Canada
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada
Canada, Ontario
Research Site
Etobicoke, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Scarborough, Ontario, Canada
Research Site
Thornhill, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Canada, Quebec
Research Site
Mirabel, Quebec, Canada
Canada
Research Site
Quebec, Canada
Chile
Research Site
Santiago, Region Metropolitana, Chile
Germany
Research Site
Damme, Germany
Research Site
Dortmund, Germany
Research Site
Homburg, Germany
Research Site
Munster, Germany
Research Site
Wangen, Germany
Hungary
Research Site
Ajka, Hungary
Research Site
Balatonfured, Hungary
Research Site
Budapest, Hungary
Research Site
Esztergom, Hungary
Research Site
Gyor, Hungary
Research Site
Komarom, Hungary
Research Site
Mosonmagyarovar, Hungary
Research Site
TAT, Hungary
Research Site
Veszprem, Hungary
Poland
Research Site
Bialystok, Poland
Research Site
Chrzanow, Poland
Research Site
Gdansk, Poland
Research Site
Grodzisk Mazowiecki, Poland
Research Site
Ilawa, Poland
Research Site
Kielce, Poland
Research Site
Krakow, Poland
Research Site
Leczna, Poland
Research Site
Leczyca, Poland
Research Site
Lodz, Poland
Research Site
Lublin, Poland
Research Site
Mragowo, Poland
Research Site
Nowy Sacz, Poland
Research Site
Plock, Poland
Research Site
Poznan, Poland
Research Site
Ruda Slaska, Poland
Research Site
Skierniewice, Poland
Research Site
Sopot, Poland
Research Site
Tarnow, Poland
Research Site
Torun, Poland
Research Site
Warszawa, Poland
Research Site
Wroclaw, Poland
Research Site
Zabrze, Poland
Research Site
Zgierz, Poland
Research Site
Zielona Gora, Poland
Sponsors and Collaborators
AstraZeneca
Bristol-Myers Squibb
Investigators
Principal Investigator: Dr. Lawrence A Leiter, MD Division of Endocrinology & Metabolism, St Michael's Hospital
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01042977     History of Changes
Other Study ID Numbers: D1690C00019
Study First Received: January 5, 2010
Results First Received: January 21, 2013
Last Updated: December 18, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
dapagliflozin
diabetes
cardiovascular disease

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Cardiovascular Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on October 19, 2014